Gainers
- WAVE Life Sciences (NASDAQ:WVE) shares moved upwards by 137.1% to $17.76 during Monday's regular session. The company's market cap stands at $1.2 billion.
- Structure Therapeutics (NASDAQ:GPCR) stock rose 100.2% to $69.19. The company's market cap stands at $2.0 billion.
- Fulcrum Therapeutics (NASDAQ:FULC) stock increased by 61.12% to $14.34. The market value of their outstanding shares is at $481.4 million.
- Kymera Therapeutics (NASDAQ:KYMR) shares rose 50.66% to $100.37. The company's market cap stands at $4.7 billion.
- Immutep (NASDAQ:IMMP) shares rose 46.11% to $2.63. The company's market cap stands at $264.9 million.
- iBio (NASDAQ:IBIO) stock rose 45.13% to $1.74. The market value of their outstanding shares is at $26.9 million.
Losers
- Meihua Intl Medical Techs (NASDAQ:MHUA) shares fell 39.2% to $8.52 during Monday's regular session. The market value of their outstanding shares is at $783.7 million.
- BiomX (AMEX:PHGE) shares fell 36.95% to $3.26. The company's market cap stands at $7.8 million.
- GRI Bio (NASDAQ:GRI) stock fell 34.96% to $1.34. The market value of their outstanding shares is at $6.7 million.
- Inspire Veterinary (NASDAQ:IVP) stock decreased by 24.3% to $0.08.
- Polyrizon (NASDAQ:PLRZ) shares fell 17.71% to $10.78. The company's market cap stands at $13.6 million.
- NeuroSense Therapeutics (NASDAQ:NRSN) shares decreased by 16.81% to $0.97. The market value of their outstanding shares is at $34.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
GPCRStructure Therapeutics Inc
$67.7596.0%
GRIGRI Bio Inc
$1.84-35.4%
IBIOiBio Inc
$1.9253.3%
IMMPImmutep Ltd
$2.6346.4%
IVPInspire Veterinary Partners Inc
$0.0811-24.5%
KYMRKymera Therapeutics Inc
$88.9452.6%
MHUAMeihua International Medical Technologies Co Ltd
$8.84-37.0%
NRSNNeuroSense Therapeutics Ltd
$0.9824-16.0%
PHGEBiomX Inc
$3.36-35.0%
PLRZPolyrizon Ltd
$10.76-17.9%
WVEWAVE Life Sciences Ltd
$18.11141.8%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

